Medicago, GSK to begin late-stage studies for COVID-19 vaccine candidate

The news comes days after early-stage data showed Medicago’s plant-based vaccine candidate produced virus-neutralizing antibodies in all volunteers. A lower dose of the vaccine will be used for further trials, Medicago said. The mid-to-late-stage clinical studies will test the safety and immune response capabilities of a regimen involving two doses of the vaccine with GSK’s pandemic adjuvant given 21 days apart, the companies said.